Cargando…

Lactoferrin as potential preventative and adjunct treatment for COVID-19

The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Raymond, Ng, Tzi Bun, Sun, Wei-Zen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390755/
https://www.ncbi.nlm.nih.gov/pubmed/32738305
http://dx.doi.org/10.1016/j.ijantimicag.2020.106118
_version_ 1783564506709884928
author Chang, Raymond
Ng, Tzi Bun
Sun, Wei-Zen
author_facet Chang, Raymond
Ng, Tzi Bun
Sun, Wei-Zen
author_sort Chang, Raymond
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes COVID-19, but few have been clinically established. Lactoferrin (Lf) is a naturally occurring, non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro antiviral efficacy against a wide range of viruses, including SARS-CoV, a closely related coronavirus to SARS-CoV-2. Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. Here we review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19.
format Online
Article
Text
id pubmed-7390755
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-73907552020-07-30 Lactoferrin as potential preventative and adjunct treatment for COVID-19 Chang, Raymond Ng, Tzi Bun Sun, Wei-Zen Int J Antimicrob Agents Article The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes COVID-19, but few have been clinically established. Lactoferrin (Lf) is a naturally occurring, non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro antiviral efficacy against a wide range of viruses, including SARS-CoV, a closely related coronavirus to SARS-CoV-2. Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. Here we review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19. Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020-09 2020-07-30 /pmc/articles/PMC7390755/ /pubmed/32738305 http://dx.doi.org/10.1016/j.ijantimicag.2020.106118 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chang, Raymond
Ng, Tzi Bun
Sun, Wei-Zen
Lactoferrin as potential preventative and adjunct treatment for COVID-19
title Lactoferrin as potential preventative and adjunct treatment for COVID-19
title_full Lactoferrin as potential preventative and adjunct treatment for COVID-19
title_fullStr Lactoferrin as potential preventative and adjunct treatment for COVID-19
title_full_unstemmed Lactoferrin as potential preventative and adjunct treatment for COVID-19
title_short Lactoferrin as potential preventative and adjunct treatment for COVID-19
title_sort lactoferrin as potential preventative and adjunct treatment for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390755/
https://www.ncbi.nlm.nih.gov/pubmed/32738305
http://dx.doi.org/10.1016/j.ijantimicag.2020.106118
work_keys_str_mv AT changraymond lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19
AT ngtzibun lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19
AT sunweizen lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19